Teva Pharmaceutical Industries (TEVA) Other Accumulated Expenses (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Other Accumulated Expenses for 18 consecutive years, with $987.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Accumulated Expenses rose 5.0% year-over-year to $987.0 million; the trailing twelve-month figure through Jun 2026 stood at $987.0 million (up 5.0% YoY), and the FY2025 full-year result was $1.2 billion, up 15.88% from the prior year.
• Other Accumulated Expenses retreated to $987.0 million in Q2 2026 per TEVA's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $1.2 billion in Q3 2024 and bottomed at $900.0 million in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $1.0 billion across 5 years, with a median of $1.0 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses grew 22.75% in 2024, then declined 21.07% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $1.0 billion in 2022, then grew by 3.88% to $1.0 billion in 2023, then dropped by 2.3% to $1.0 billion in 2024, then gained by 15.88% to $1.2 billion in 2025, then dropped by 16.5% to $987.0 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $987.0 million, $1.1 billion, and $1.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.